摘要
新型冠状病毒肺炎(Coronavirus Disease 2019, COVID-19)由于其高传播率及人群普遍易感性成为威胁生命的全球健康负担。全国广泛推行新型冠状病毒疫苗接种以产生群体免疫。我国现存超3亿的慢性肝病患者,有研究表明,慢性肝病患者较健康人群对COVID-19有更高的易感性,且慢性肝病患者感染COVID-19后的重症率和死亡率升高,接种新冠疫苗可以有效降低新冠感染后的重症率和死亡率。目前有部分关于这一特殊人群接种新冠疫苗的安全性和有效性研究。本综述叙述了慢性肝病与COVID-19之间的关系,也叙述了新冠肺炎疫苗在慢性肝病这一特殊人群中的安全性和有效性。
Coronavirus Disease 2019 (COVID-19) has become a life-threatening global health burden due to its rapid transmission rate and general susceptibility. Vaccination against SARS-Cov-2 was actively promoted worldwide. There are more than 300 million patients with chronic liver diseases in China. Patients with chronic liver diseases have a higher susceptibility to COVID-19 than healthy people. They are considered to be at a high risk for severe COVID-19 and death. SARS-Cov-2 vaccination can reduce the disease severity and mortality effectively. There are some studies on the safety and effi-cacy of COVID-19 vaccination in patients with chronic liver diseases. This review focuses on the role of COVID-19 in chronic liver diseases and the safety and efficacy of COVID-19 vaccination in this spe-cial population.
出处
《临床医学进展》
2023年第6期9060-9066,共7页
Advances in Clinical Medicine
